NTLA Stock Price Today (September 2026) — Intellia Therapeutics, Inc. Analysis & Key Metrics 2026-09-03
Intellia Therapeutics, Inc. (NTLA) is trading at $12.68, down 0.63% today (as of September 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $25.94 (104.6% upside).
- Volatility remains elevated (65.42% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-46.20% YoY) alongside significant competitive pressures.
NTLA Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Intellia Therapeutics, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $1.44B
P/E Ratio
Forward P/E: -4.89
Revenue Growth
Year over Year
Analyst Target
+104.6% upside potential
Key Investor Questions About NTLA
What investors need to know before buying
Based on current market data, NTLA presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 52.09)
- Fundamentals say: Challenging (declining revenue trends)
NTLA's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NTLA investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $73.41M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, NTLA stock traded between $7.95 and $28.25—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 65.42% annualized volatility and β=1.75, the stock exhibits high sensitivity to market moves—making NTLA suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Ark Invest was a buyer of tech stocks down as much as 53% from their recent all-time highs.
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets
Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war chest.
Intellia (NTLA) Q2 2026 Earnings Call Transcript
Lonvo-z Phase III trial met primary endpoint with 87% attack reduction versus placebo.
These Are the Stocks Wall Street Is Betting Against the Most
Wolfspeed, BigBear.ai and Others Face Heavy Short-Seller Pressure
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.
Intellia Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Intellia Therapeutics, Inc.'s Q2 2026 earnings call
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.
Will Intellia’s (NTLA) Narrowing Losses and Heavy R&D Spend Shift Its Risk Reward Narrative?
On August 6, 2026, Intellia Therapeutics reported second-quarter results showing a net loss of US$106.63 million and basic and diluted loss per share of US$0.80, compared with a net loss of US$101.26 million and loss per share of US$0.98 a year earlier. Over the first six months of 2026, Intellia reduced its net loss to US$202.87 million from US$215.58 million, while cutting basic and diluted loss per share from US$2.08 to US$1.61, pointing to some improvement in loss per share despite...
Intellia Therapeutics Q2 Earnings Call Highlights
Intellia Therapeutics (NASDAQ:NTLA) said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis. Chief Executive O
Explore More Analysis for NTLA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NTLA) is currently trading at $12.68. The RSI (14-day) is at 52.1, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $25.94 implies 104.6% upside from current levels. Volatility is high at 65.4% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Intellia Therapeutics, Inc. (NTLA): The trailing P/E ratio is -3.80, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -4.89, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 2.44. Price-to-Sales is 29.86. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 17 analysts covering NTLA, the consensus price target is $25.94. This represents a 104.6% upside from the current price of $12.68. The range spans from a low target of $8.00 to a high target of $95.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Intellia Therapeutics, Inc. (NTLA) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Intellia Therapeutics, Inc. (NTLA) investors include: 1. High volatility (65.4% annualized)—the stock can experience significant daily price swings. 2. Declining revenue (-46.2% YoY), indicating potential business headwinds. 3. Elevated short interest (41.3% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Intellia Therapeutics, Inc.'s (NTLA) current debt and financial health profile: Total debt stands at $73.41M. The debt-to-equity ratio is 10.09, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 6.65, indicating strong short-term liquidity. The quick ratio is 5.61. The company holds $437.76M in cash and equivalents. Free cash flow is negative at $-249,825,376, which could limit the company's ability to manage debt obligations.